$VRTC
VERITEC INC Stock $vrtc

$vrtc Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-K Financial Statement

#000171328224001164 Filed on October 10, 2024

Income Statement

Concept	2024 Q4	2024 Q2	2024
Revenue		$160.0K	$461.0K
YoY Change		162.3%	29.49%
Cost Of Revenue		$39.00K	$173.0K
YoY Change		-4.88%	-18.01%
Gross Profit		$121.0K	$288.0K
YoY Change		505.0%	98.62%
Gross Profit Margin		75.63%	62.47%
Selling, General & Admin		$191.0K	$796.0K
YoY Change		-2.55%	-9.85%
% of Gross Profit		157.85%	276.39%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses		$191.0K	$969.0K
YoY Change		-2.55%	9.74%
Operating Profit		-$70.00K	-$508.0K
YoY Change		-60.23%	-31.17%
Interest Expense		-$139.0K	-$550.0K
YoY Change		7.75%	-210.89%
% of Operating Profit
Other Income/Expense, Net			-$550.0K
YoY Change			-257.14%
Pretax Income		-$209.0K	-$1.058M
YoY Change		-31.48%	-14.26%
Income Tax			$0.00
% Of Pretax Income
Net Earnings		-$209.0K	-$1.058M
YoY Change		-31.48%	-14.26%
Net Earnings / Revenue		-130.63%	-229.5%
Basic Earnings Per Share			-$0.03
Diluted Earnings Per Share		-$0.01	-$0.03
COMMON SHARES
Basic Shares Outstanding	39.94M shares	39.99M shares	39.98M shares
Diluted Shares Outstanding			39.98M shares

Balance Sheet

Concept	2024 Q2	2024
SHORT-TERM ASSETS
Cash & Short-Term Investments	$118.0K	$118.0K
YoY Change	93.44%	93.44%
Cash & Equivalents	$0.00
Short-Term Investments
Other Short-Term Assets	$6.000K	$6.000K
YoY Change	0.0%	0.0%
Inventory
Prepaid Expenses
Receivables	$8.000K	$8.000K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$132.0K	$132.0K
YoY Change	78.38%	78.38%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$0.00	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$132.0K	$132.0K
Total Long-Term Assets	$0.00	$0.00
Total Assets	$132.0K	$132.0K
YoY Change	78.38%	78.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$268.0K	$377.0K
YoY Change	-7.27%	-7.6%
Accrued Expenses	$60.00K	$60.00K
YoY Change	0.0%	0.0%
Deferred Revenue	$29.00K
YoY Change	0.0%
Short-Term Debt	$8.996M	$8.996M
YoY Change	13.99%	13.99%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$9.462M	$9.462M
YoY Change	12.79%	12.79%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$398.0K	$398.0K
YoY Change	12.11%	12.11%
Total Long-Term Liabilities	$398.0K	$398.0K
YoY Change	12.11%	12.11%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.462M	$9.462M
Total Long-Term Liabilities	$398.0K	$398.0K
Total Liabilities	$9.860M	$9.860M
YoY Change	12.76%	12.76%
SHAREHOLDERS EQUITY
Retained Earnings	-$28.28M
YoY Change	3.89%
Common Stock	$400.0K
YoY Change	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$9.728M	-$9.728M
YoY Change
Total Liabilities & Shareholders Equity	$132.0K	$132.0K
YoY Change	78.38%	78.38%

Cashflow Statement

Concept	2024 Q2	2024
OPERATING ACTIVITIES
Net Income	-$209.0K	-$1.058M
YoY Change	-31.48%	-14.26%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$93.00K	-$496.0K
YoY Change	-54.85%	-0.6%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	58.00K	$553.0K
YoY Change	-58.27%	11.94%
NET CHANGE
Cash From Operating Activities	-93.00K	-$496.0K
Cash From Investing Activities
Cash From Financing Activities	58.00K	$553.0K
Net Change In Cash	-35.00K	$57.00K
YoY Change	-47.76%	-1240.0%
FREE CASH FLOW
Cash From Operating Activities	-$93.00K	-$496.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0000773318
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther		usd
CY2024	dei	Document Type DocumentType	10-K
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2024	dei	Document Transition Report DocumentTransitionReport	false
CY2024	dei	Entity File Number EntityFileNumber	000-15113
CY2024	dei	Entity Registrant Name EntityRegistrantName	VERITEC, INC.
CY2024	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2024	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	95-3954373
CY2024	dei	Entity Address Address Line1 EntityAddressAddressLine1	2445 Winnetka Avenue N.
CY2024	dei	Entity Address City Or Town EntityAddressCityOrTown	Golden Valley
CY2024	dei	Entity Address State Or Province EntityAddressStateOrProvince	MN
CY2024	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	55427
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2024	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	true
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Public Float EntityPublicFloat	305000	usd
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	39938007	shares
CY2024	dei	Auditor Name AuditorName	Weinberg & Company, P.A.
CY2024	dei	Auditor Location AuditorLocation	Los Angeles, California
CY2024	dei	Auditor Firm AuditorFirmId	572
CY2024Q2	us-gaap	Cash Cash	118000	usd
CY2023Q2	us-gaap	Cash Cash	61000	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8000	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7000	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6000	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	132000	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	74000	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	268000	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	289000	usd
CY2024Q2	VRTC	Accounts Payable Related Party Current AccountsPayableRelatedPartyCurrent	109000	usd
CY2023Q2	VRTC	Accounts Payable Related Party Current AccountsPayableRelatedPartyCurrent	119000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	60000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	60000	usd
CY2024Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	29000	usd
CY2023Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	29000	usd
CY2024Q2	VRTC	Convertible Notes And Notes Payable In Default ConvertibleNotesAndNotesPayableInDefault	543000	usd
CY2023Q2	VRTC	Convertible Notes And Notes Payable In Default ConvertibleNotesAndNotesPayableInDefault	525000	usd
CY2024Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	591000	usd
CY2023Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	570000	usd
CY2024Q2	VRTC	Convertible Notes And Notes Payable Related Party In Default ConvertibleNotesAndNotesPayableRelatedPartyInDefault	251000	usd
CY2023Q2	VRTC	Convertible Notes And Notes Payable Related Party In Default ConvertibleNotesAndNotesPayableRelatedPartyInDefault	242000	usd
CY2024Q2	VRTC	Convertible Notes And Notes Payable Related Parties Current ConvertibleNotesAndNotesPayableRelatedPartiesCurrent	8405000	usd
CY2023Q2	VRTC	Convertible Notes And Notes Payable Related Parties Current ConvertibleNotesAndNotesPayableRelatedPartiesCurrent	7322000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	9462000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	8389000	usd
CY2024Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	243000	usd
CY2023Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	200000	usd
CY2024Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	155000	usd
CY2023Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	155000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	9860000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	8744000	usd
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	1.00
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	1.00
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue	1000	usd
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue	1000	usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39938007	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39938007	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39988007	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39988007	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	400000	usd
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	400000	usd
CY2024Q2	VRTC	Common Stock To Be Issued Shares CommonStockToBeIssuedShares	145000	shares
CY2023Q2	VRTC	Common Stock To Be Issued Shares CommonStockToBeIssuedShares	145000	shares
CY2024Q2	VRTC	Common Stock To Be Issued CommonStockToBeIssued	12000	usd
CY2023Q2	VRTC	Common Stock To Be Issued CommonStockToBeIssued	12000	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	18143000	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	18143000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-28284000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-27226000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-9728000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-8670000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	132000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	74000	usd
CY2024	us-gaap	Revenues Revenues	461000	usd
CY2023	us-gaap	Revenues Revenues	356000	usd
CY2024	VRTC	Cost Of Revenues CostOfRevenues	173000	usd
CY2023	VRTC	Cost Of Revenues CostOfRevenues	211000	usd
CY2024	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	796000	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	883000	usd
CY2024	us-gaap	Operating Expenses OperatingExpenses	969000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	1094000	usd
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	-508000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-738000	usd
CY2024	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	550000	usd
CY2023	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	496000	usd
CY2024	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-550000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-496000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-1058000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1234000	usd
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39978034	shares
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39978034	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39988007	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39988007	shares
CY2024	VRTC	Includes Expenses To Related Party IncludesExpensesToRelatedParty	51000	usd
CY2023	VRTC	Includes Expenses To Related Party IncludesExpensesToRelatedParty	51000	usd
CY2024	VRTC	Includes Interest Expense To Related Parties IncludesInterestExpenseToRelatedParties	531000	usd
CY2023	VRTC	Includes Interest Expense To Related Parties IncludesInterestExpenseToRelatedParties	475000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-7436000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1234000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-8670000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-1058000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-9728000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-1058000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1234000	usd
CY2024	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	551000	usd
CY2023	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	495000	usd
CY2024	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-0	usd
CY2024	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	4000	usd
CY2024	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	43000	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	200000	usd
CY2024	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-21000	usd
CY2023	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	18000	usd
CY2024	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-10000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	17000	usd
CY2024	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	0	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1000	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-496000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-499000	usd
CY2024	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	586000	usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	494000	usd
CY2024	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	33000	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	-0	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	553000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	494000	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	57000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-5000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	61000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	66000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	118000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	61000	usd
CY2024	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2024	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-1058000	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-496000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-9728000	usd
CY2024Q2	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	794000	usd
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84E_eus-gaap--UseOfEstimates_zRgpHzFRuwic" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><span id="xdx_86E_zkzky5G3Iej2">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; margin-top: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of revenues and expenses during the reporting period. Those estimates and assumptions include estimates for accruals for potential liabilities, and valuation of deferred tax assets. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p>
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	0	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	0	usd
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2024	us-gaap	Proceeds From License Fees Received ProceedsFromLicenseFeesReceived	150000	usd
CY2024	us-gaap	Revenues Revenues	461000	usd
CY2023	us-gaap	Revenues Revenues	356000	usd
CY2024	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	33075618	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	28811581	shares
CY2024	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zCLbr6dEzy21" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><span id="xdx_86E_zXc0fMfNFR2c">Concentrations</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif">During the year ended June 30, 2024, the Company had one customer that represented <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z6O4yt7r4Uge" title="Concentration risk, percentage">37</span>% (related party) of our revenues, one customer that represented <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zWt0CAMcwXq4" title="Concentration risk, percentage">33</span>% of our revenues and one customer that represented <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z2TnErNV1wYk" title="Concentration risk, percentage">22</span>% of our revenues. No other customer represented more than 10% of our revenues.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif">During the year ended June 30, 2023, the Company had three customers, that represented <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20220701__20230630__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_znl9Jcasfbi9" title="Concentration risk, percentage">61</span>% (a related party), <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20220701__20230630__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zd8UPTiOBdkf" title="Concentration risk, percentage">14</span>% and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20220701__20230630__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z4A8sWJX5pI5" title="Concentration risk, percentage">13</span>% of our revenues, respectively. No other customer represented more than 10% of our revenues. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif">At June 30, 2024, the Company substantially had three customers that represented <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zPyLmEMd9Zf7" title="Concentration risk, percentage">52</span>%, <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zXN7lgVhozgi" title="Concentration risk, percentage">15</span>% and <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240630__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zLhIcqO8Fygj" title="Concentration risk, percentage">15</span>% of accounts receivable. As of June 30, 2023, , the Company substantially had three customers that represented <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20220701__20230630__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zHkEL0z4lGyd" title="Concentration risk, percentage">55</span>%, <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20220701__20230630__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z9Pg1RCzCtBa" title="Concentration risk, percentage">17</span>% and <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_dp_c20220701__20230630__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z0ZBJguN9Jdf" title="Concentration risk, percentage">17</span>% of accounts receivable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif"> </span></p>
CY2024Q2	us-gaap	Notes Payable NotesPayable	591000	usd
CY2023Q2	us-gaap	Notes Payable NotesPayable	570000	usd
CY2024Q2	us-gaap	Notes And Loans Payable NotesAndLoansPayable	8405000	usd
CY2023Q2	us-gaap	Notes And Loans Payable NotesAndLoansPayable	7322000	usd
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	1.00
CY2024Q2	VRTC	Common Stock To Be Issued Shares CommonStockToBeIssuedShares	145000	shares
CY2023Q2	VRTC	Common Stock To Be Issued Shares CommonStockToBeIssuedShares	145000	shares
CY2024Q2	VRTC	Common Stock To Be Issued CommonStockToBeIssued	12000	usd
CY2023Q2	VRTC	Common Stock To Be Issued CommonStockToBeIssued	12000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	900000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.03
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	-0	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	-0
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	900000	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.03
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	350000	shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.03
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	550000	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.03
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	550000	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.03
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	usd
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	5500	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	550000	shares
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P0Y6M
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.03
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-1058000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1234000	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024	VRTC	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rates EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates	0.21	pure
CY2023	VRTC	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rates EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates	0.21	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.06	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.06	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.27	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.27	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.27	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.27	pure
CY2024	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2024Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	4590000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	4315000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	4590000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	4315000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4590000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4315000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2024	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	275000	usd
CY2024Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	17000000	usd
CY2024Q2	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	usd
CY2023Q2	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	usd
CY2024	us-gaap	Proceeds From Customers ProceedsFromCustomers	200000	usd
CY2024Q2	us-gaap	Contract With Customer Refund Liability Current ContractWithCustomerRefundLiabilityCurrent	150000	usd
CY2024Q2	VRTC	Additional Contract With Customer Liability Current AdditionalContractWithCustomerLiabilityCurrent	50000	usd
CY2024	VRTC	License Agreement Minimum Payment Description LicenseAgreementMinimumPaymentDescription	Per the agreement, the Company will also receive a minimum payment of $60,000 per month in the first year of the agreement, commencing after 120 days, $120,000 per month in the second year and $180,000 per month in the third year.
CY2024	us-gaap	Proceeds From License Fees Received ProceedsFromLicenseFeesReceived	150000	usd
CY2024	us-gaap	Proceeds From License Fees Received ProceedsFromLicenseFeesReceived	150000	usd
CY2024	us-gaap	Proceeds From License Fees Received ProceedsFromLicenseFeesReceived	150000	usd
CY2024Q2	us-gaap	Contract With Customer Refund Liability ContractWithCustomerRefundLiability	150000	usd
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001713282-24-001164-index-headers.html	Edgar Link	pending
0001713282-24-001164-index.html	Edgar Link	pending
0001713282-24-001164.txt	Edgar Link	pending
0001713282-24-001164-xbrl.zip	Edgar Link	pending
ex31_1.htm	Edgar Link	pending
ex32_1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
veritec063024form10k.htm	Edgar Link	pending
vrtc-20240630.xsd	Edgar Link	pending
vrtc-20240630_cal.xml	Edgar Link	unprocessable
vrtc-20240630_def.xml	Edgar Link	unprocessable
vrtc-20240630_lab.xml	Edgar Link	unprocessable
vrtc-20240630_pre.xml	Edgar Link	unprocessable
veritec063024form10k_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VRTC
VERITEC INC Stock $vrtc

2024 Q4 Form 10-K Financial Statement

#000171328224001164 Filed on October 10, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRTC VERITEC INC Stock $vrtc

2024 Q4 Form 10-K Financial Statement

#000171328224001164 Filed on October 10, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRTC
VERITEC INC Stock $vrtc